Dianthus Therapeutics, Inc.DNTHNASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
-15.35%
↓ 24% below average
Average (34q)
-12.38%
Historical baseline
Range
High:55.41%
Low:-226.98%
Volatility
-2281.4%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | -15.35% |
| Q2 2025 | -5.27% |
| Q1 2025 | -3.95% |
| Q4 2024 | -6.74% |
| Q3 2024 | -34.66% |
| Q2 2024 | -24.43% |
| Q1 2024 | -37.73% |
| Q4 2023 | 17.79% |
| Q3 2023 | -33.82% |
| Q2 2023 | -53.27% |
| Q1 2023 | 28.15% |
| Q4 2022 | -29.55% |
| Q3 2022 | 54.35% |
| Q2 2022 | 24.13% |
| Q1 2022 | -18.34% |
| Q4 2021 | -10.39% |
| Q3 2021 | -3.61% |
| Q2 2021 | 5.81% |
| Q1 2021 | 1.93% |
| Q4 2020 | -3.72% |
| Q3 2020 | 8.15% |
| Q2 2020 | 5.80% |
| Q1 2020 | 13.77% |
| Q4 2019 | -8.80% |
| Q3 2019 | -17.10% |
| Q2 2019 | -18.28% |
| Q1 2019 | 8.81% |
| Q4 2018 | -7.35% |
| Q3 2018 | -19.09% |
| Q2 2018 | -24.05% |
| Q1 2018 | -38.38% |
| Q4 2017 | -16.46% |
| Q3 2017 | 55.41% |
| Q2 2017 | -226.98% |
| Q1 2017 | 0.00% |